Skip to main content
Retour
TBPH logo

Theravance Biopharma, Inc.

Qualité des données : 100%
TBPH
NASDAQ Healthcare Biotechnology
14,90 €
▲ 0,15 € (1,02%)
Cap. Boursière : 755,02M
Fourchette du Jour
14,59 € 14,97 €
Fourchette 52 Semaines
7,90 € 21,03 €
Volume
539 448
Moyenne 50J / 200J
17,97 € / 15,18 €
Clôture Précédente
14,75 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 7,1 0,3
P/B 2,5 2,9
ROE % 44,9 3,7
Net Margin % 98,5 3,8
Rev Growth 5Y % 18,1 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Hold
27,00 € +81.2%
Low: 14,00 € High: 40,00 €
P/E Prévisionnel
7,1
BPA Prévisionnel
2,09 €
Croissance BPA (est.)
+0,0%
CA Est.
120 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 1,01 €
0,75 € – 1,54 €
 100 M 2
FY2029 0,85 €
0,63 € – 1,29 €
 96 M 4
FY2028 0,76 €
0,09 € – 1,51 €
 92 M 6

Insider Trading Activity

17 transactions
Date Insider Type Shares Price Value
Feb 20, 2026
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 74 975 19,66 € 1 474 009 €
Feb 20, 2026
Sawaf Aziz
SVP & CHIEF FINANCIAL OFFICER
 other 20 672 19,66 € 406 412 €
Feb 20, 2026
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
 other 13 929 19,66 € 273 844 €
Feb 20, 2026
Miller Aine
SVP, DEV & HEAD OF IRE OFFICE
 other 16 851 19,66 € 331 291 €
Nov 20, 2025
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
 other 9 060 17,90 € 162 174 €
Nov 20, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 56 817 17,90 € 1 017 024 €
Nov 19, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 19 800 — —
Aug 20, 2025
Sawaf Aziz
SVP & CHIEF FINANCIAL OFFICER
 other 9 368 13,39 € 125 438 €
Aug 20, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 15 394 13,39 € 206 126 €
Aug 20, 2025
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
 other 9 096 13,39 € 121 795 €
Aug 20, 2025
Miller Aine
SVP, DEV & HEAD OF IRE OFFICE
 other 6 989 13,39 € 93 583 €
Jun 23, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 20 000 — —
Jun 2, 2025
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
 sell 24 000 11,00 € 264 000 €
May 20, 2025
Sawaf Aziz
SVP & CHIEF FINANCIAL OFFICER
 other 9 348 9,45 € 88 339 €
May 20, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 15 364 9,45 € 145 190 €
May 19, 2025
GRAY SUSANNAH
 grant 34 907 — —
May 19, 2025
Smaldone Alsup Laurie
 grant 34 907 — —

Points Clés

Revenue grew 18,06% annually over 5 years — strong growth
ROE of 44,85% indicates high profitability
Net margin of 98,54% shows strong profitability
Debt/Equity of 0,14 — conservative balance sheet
Generating 238,50M in free cash flow
P/E of 7,13 — trading at a low valuation

Croissance

Revenue Growth (5Y)
18,06%
Revenue (1Y)66,92%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
44,85%
ROIC-0,80%
Net Margin98,54%
Op. Margin-3,35%

Sécurité

Debt / Equity
0,14
Current Ratio10,93
Interest Coverage-1,46

Valorisation

P/E Ratio
7,13
P/B Ratio2,54
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 66,92% Revenue Growth (3Y) 36,80%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 18,06% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 107,46M Net Income (TTM) 105,90M
ROE 44,85% ROA 21,81%
Gross Margin 0,00% Operating Margin -3,35%
Net Margin 98,54% Free Cash Flow (TTM) 238,50M
ROIC -0,80% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,14 Current Ratio 10,93
Interest Coverage -1,46 Dividend Yield 0,00%
Valuation
P/E Ratio 7,13 P/B Ratio 2,54
P/S Ratio 7,03 PEG Ratio -0,03
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 755,02M Enterprise Value 629,92M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 107,46M 64,38M 57,42M 51,35M 55,31M
Net Income 105,90M -56,42M -55,19M 872,13M -199,43M
EPS (Diluted) 2,06 -1,15 -1,00 -1,26 -2,87
Gross Profit 0,0 64,38M 16,80M -12,05M -138,35M
Operating Income -3,60M -46,95M -56,04M -91,96M -257,78M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 485,57M 354,16M 382,00M 607,40M 374,82M
Total Liabilities 188,85M 178,62M 169,00M 165,60M 713,39M
Shareholders' Equity 296,72M 175,55M 213,00M 441,80M -338,57M
Total Debt 42,70M 49,82M 49,16M 52,16M 669,52M
Cash & Equivalents 167,81M 37,80M 39,55M 298,17M 89,96M
Current Assets 418,46M 161,07M 133,54M 353,46M 249,87M
Current Liabilities 38,30M 32,09M 24,77M 28,72M 58,59M

Scores de Stratégies

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#158 of 1052
65
Custom Capital Light Compounder
#7 of 218
75
Custom Contrarian Investing (David Dreman)
#30 of 670
78
Value Value Investing (Warren Buffett)
#8 of 203
62

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026
Entré Capital Light Compounder
Mar 24, 2026
Entré Contrarian Investing (David Dreman)
Mar 24, 2026
Entré Value Investing (Warren Buffett)
Mar 24, 2026